Omnicell, Inc. (NASDAQ: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, appointed Nnamdi Njoku as President of the company, effective July 1, 2026. Mr. Njoku will retain his role as Chief Operating Officer (COO), while Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board. The leadership change aims to strengthen the company's operational foundation and strategic direction as it scales global operations.

Strategic Focus and Responsibilities

As President and COO, Mr. Njoku will shape and advance Omnicell’s long-term growth strategy and innovation roadmap. His responsibilities include ensuring seamless operational execution across product, innovation, and customer experience. He will continue to drive key business initiatives, such as the launch of the Omnicell Titan XT automated dispensing system and the expansion of the cloud-native OmniSphere platform.

Leadership Background

Mr. Njoku joined Omnicell in 2024. Prior to this, he served for over 18 years in executive leadership roles at Medtronic plc, including as Senior Vice President and President for the Neuromodulation Operating Unit, an approximately $2 billion business. His career also includes operational roles at Zimmer Biomet Holdings, Inc., UnitedHealth Group, and Deloitte Consulting.

Executive Commentary

"Since joining Omnicell in 2024, Nnamdi has made a significant strategic impact on the Company, working to strengthen our operational foundation, shape our strategic direction and organizational design," said Mr. Lipps. "This appointment reflects a natural evolution of our leadership structure and allows me to be laser-focused on strategic customer and industry relationships."

Mr. Njoku holds a Master of Business Administration from Cornell University and a Bachelor of Arts degree in Business Administration from the University of St. Thomas. He is a Fellow of the Aspen Institute’s Health Innovators Fellowship and a member of the Aspen Global Leadership Network.